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ABSTRACT
Clinical and laboratory diagnosis and treatment of central precocious puberty (CPP) remain chal-
lenging due to lack of standardization. The aim of this revision was to address the diagnostic and 
therapeutic features of CPP in Brazil based on relevant international literature and availability of the 
existing therapies in the country. The diagnosis of CPP is based mainly on clinical and biochemical 
parameters, and a period of follow-up is desirable to define the “progressive” form of sexual precoc-
ity. This occurs due to the broad spectrum of pubertal development, including isolated premature 
thelarche, constitutional growth and puberty acceleration, progressive and nonprogressive CPP, and 
early puberty. Measurement of basal and stimulated LH levels remains challenging, considering that 
the levels are not always in the pubertal range at baseline, short-acting GnRH is not readily available 
in Brazil, and the cutoff values differ according to the laboratory assay. When CPP is suspected but 
basal LH values are at prepubertal range, a stimulation test with short-acting or long-acting monthly 
GnRH is a diagnostic option. In Brazil, the treatment of choice for progressive CPP and early puberty 
is a long-acting GnRH analog (GnRHa) administered once a month or every 3 months. In Brazil, for-
mulations of GnRHa (leuprorelin and triptorelin) are available and commonly administered, includ-
ing 1-month depot leuprorelin 3.75 mg and 7.5 mg, 1-month depot triptorelin 3.75 mg, and 3-month 
depot leuprorelin 11.25 mg. Monthly or 3-month depot GnRHa are effective and safe to treat CPP. Arch 
Endocrinol Metab. 2016;60(2):163-72
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INTRODUCTION
P uberty is a period of physical, hormonal, and psy-chological transition from childhood to adult-
hood, with accelerated linear growth and achievement 
of reproductive function. It is a complex and multifac-
torial process that includes genetic, metabolic, environ-
mental, ethnic, geographic, and economic factors and 
results in reactivation of the hypothalamic-pituitary-go-
nadal (HPG) axis. An effective pubertal onset requires 
pulsatile hypothalamic secretion of GnRH stimulating 
the secretion of gonadotropins by the anterior pituitary 
gland (LH = luteinizing hormone and FSH = follicle-
stimulating hormone). Gonadotropins stimulate the 
gonads and exert a negative feedback effect on the hy-
pothalamus, whereas gonadal steroids (T = testoster-
one, produced by the testis, and E2 = estradiol, pro-
duced by the ovaries) inhibit both hypothalamus and 
anterior pituitary gland. This process is named gonad-
arche (1-3).
Gonadarche is often preceded by adrenarche, a 
process ACTH-independent (adrenocorticotropic hor-
mone) and responsible for the secretion of androgens 
(DHEA = dehydroepiandrosterone and DHEAS = 
DHEA sulfate) by the adrenal zona reticularis. Adrenar-
che is clinically characterized by development of axillary 
odor, pubic hair, and skin oiliness, whereas in gonadar-
che the initial clinical manifestation is thelarche in girls 
and a bilateral increase in testicular volume in boys (4).
The classical definition of precocious puberty is the 
development of secondary sexual characteristics before 
the age of 8 years or menarche before the age of 9 years 
in girls and any secondary sexual characteristic before 
the age of 9 years in boys. However, recent epidemiolo-
gical studies have suggested that the initial pubertal age 
is decreasing mainly in girls (5-7), but also in boys (8,9).
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CLASSIFICATION OF PRECOCIOUS PUBERTY
Precocious puberty is classified according to the un-
derlying physiopathological process (10) in:
• Variants of normal pubertal development: iso-
lated forms of thelarche, pubarche, or vaginal 
bleeding due or not to a hormonal etiology;
• Central precocious puberty (CPP), gonadotro-
pin-dependent precocious puberty, or true preco-
cious puberty: early maturation of the HPG axis;
• Peripheral precocious puberty, or gonadotro-
pin-independent precocious puberty, or pseu-
doprecocious puberty: excessive secretion of 
gonadal sex hormones or adrenal hormones 
from a genetic or tumoral etiology, germ cell 
tumors secreting hCG (human chorionic go-
nadotropin – exclusively in boys), or an exoge-
nous source.
PARTICIPANTS AND OBJECTIVE
There were 6 participants chosen for their expertise in 
pediatric and adult endocrinology. Therefore, a meeting 
was organized in Sao Paulo, Brazil, in October 2015, 
with representation from Brazilian Society for Endocri-
nology and Metabolism and Brazilian Pediatric Society, 
Departments of Pediatric Endocrinology, to examine 
current data relevant to the diagnosis and therapeutic 
management of children with CPP. This revision pre-
sents a summary of essential issues on this topic.
The aim of this revision was to address the diagnosis 
and therapeutic management of CPP based on relevant 
international literature and availability of the existing 
medications in Brazil.
CENTRAL PRECOCIOUS PUBERTY
Etiology
The main etiologies of CPP are listed in Table 1 (10-
15). Idiopathic CPP represents 90% of the cases in girls, 
whereas organic etiologies are more frequent (60% to 
70%) in boys. However, these epidemiological data are 
currently being revised with the new genetic and ima-
ging diagnostic methods (8).
Clinical diagnosis
From a clinical standpoint, puberty onset and rate of 
progression are determined by the observation of phy-
sical changes. In girls, estrogen determines the deve-
lopment of breasts, enlargement of labia majora and 
minora, and increase and redistribution of body fat 
predominantly in the hips. Another important aspect 
is the estrogenization of the vaginal epithelium, with 
acidification of the vaginal pH and mucus discharge. In 
response to testosterone, boys present testicular, penile, 
and cricoid cartilage growth (leading to voice change), 
facial hair development, changes in body fat distribu-
tion, and increase in muscle mass. In 40% of the boys, 
transient pubertal gynecomastia may occur. In both 
genders, development of pubic hair is associated with 
adrenarche (10,16-19). The stage of female and male 
pubertal development is determined by Marshall and 
Tanner’s classification (20,21).
To evaluate a patient with precocious puberty, the 
clinician must know the normal chronology of pubertal 
events and growth rate, and the progression of bone 
maturation (Figure 1) (22). A progression from one 
stage to another in less than six months and a height 
velocity above 6 cm/year characterize a progressive 
condition. Height, weight, and height velocity should 
be plotted in reference curves, and height is generally 
found to be above the familial pattern (10,16-19).
The main objective of evaluating patients with pre-
cocious puberty is to identify benign conditions from 
others caused by diseases like tumors, which require 
Table 1. Etiologies of central precocious puberty
Idiopathic
Genetic causes
Activating mutations in the KISS1R and KISS1 genes
Inactivating mutations in the MKRN3 gene (familial CPP)
Chromosomal abmormalities
Secondary to chronic exposure to sex steroid hormones (late treatment of 
simple virilizing congenital adrenal hyperplasia, following ressection of tumors 
secreting sex steroid hormones, testoxicosis, McCune-Albright syndrome) or 
endocrine disruptors
International adoption
CNS abnormalities
Hypothalamic hamartoma
Tumors: astrocytoma, ependymoma, optic or hypothalamic glioma, 
LH-secreting adenoma, pinealoma, neurofibroma, non-hCG secreting 
dysgerminoma, craniopharyngioma*
Other congenital malformations: suprasellar cyst, arachnoid cyst, septo-optic 
dysplasia, hydrocephalus, spina bifida, vascular malformation, 
meningomyelocele, ectopic posterior pituitary lobe, pituitary duplication
Acquired diseases*: inflammatory processes (abscess, meningitis, 
encephalitis, sarcoidosis, tuberculosis), radiation, perinatal asphyxia, trauma
CNS: central nervosus system. * May also progress to pituitary dysfunction.
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immediate and objective management. Patients with 
the following characteristics must always be evaluated:
• Early onset and/or accelerated development 
of secondary sexual characteristics in both gen-
ders;
• Height velocity above the expected value for 
gender and age and/or height above the fami-
lial genetic channel.
The clinical history must always be the initial diag-
nostic step, and investigation should include the birth 
conditions, history of perinatal trauma, previous infec-
tions, accidental ingestion of drugs, and use of creams 
or ointments. It is also very important to identify prior 
neurological diseases and information such as the oc-
currence of headache and psychological, visual, or appe-
tite changes. The age at onset of signs and symptoms is 
not helpful in differential diagnosis. However, clinical 
manifestations below the age of 4 years suggest orga-
nic etiologies, particularly hypothalamic hamartomas. 
Information about family history, including the age at 
pubertal onset and similar cases in the family, may be 
useful in the diagnosis of familial CPP (10,16-19).
The physical examination must include informa-
tion about height, weight, and pubertal stage. In girls, 
the differential diagnosis of CPP may be challenging 
because the spectrum of pubertal development is very 
broad and includes isolated premature thelarche, cons-
titutional growth and puberty acceleration, progressive 
and nonprogressive CPP, and early puberty (develop-
10 11 12 13 14 15 16 17
2 3 4 5
Event
Growth velocity
Menarche
Breast
Hair
10 11 12 13 14 15 16 17
2 3 4 5
2 3 4 5
Event
 Growth velocity
Penis
Testes
Hair
1 5
Age (years) Age (years)
± 2 years ± 2 years
Female Male
Figure 1. Chronology of sexual maturation and growth spurt during puberty in both genders according to Marshall & Tanner (20,21) stages. Adapted from 
Tanner (22).
ment of secondary sexual characteristics between the 
ages of 8 and 9 years in girls and 9 and 10 years in 
boys) (23,24). In boys, testicular development is of-
ten indicative of activation of the HPG axis, whereas 
in peripheral puberty, penile growth occurs without 
concomitant testicular development, or the size of the 
testis is disproportional to the virilization of the geni-
talia. Other important assessments during physical exa-
mination that may help in the differential diagnosis of 
idiopathic and neurogenic CPP include neurological 
examination, measurement of head circumference, and 
funduscopic evaluation. The physical examination must 
also investigate the presence of neurofibromas and 
café-au-lait spots with regular edges, which are sug-
gestive of type 1 neurofibromatosis and related to CPP 
(associated with optic glioma). Café-au-lait spots with 
irregular and often jagged edges may indicate the diag-
nosis of McCune-Albright syndrome, which is associa-
ted with peripheral precocious puberty of ovarian etio-
logy (10,16-19).
Differential diagnosis of precocious puberty
It is essential to discriminate between CPP and com-
mon variants of precocious puberty, such as isolated 
premature thelarche or adrenarche and prepubertal 
vaginal bleeding due or not to a hormonal etiology. 
These conditions occur independent of the reactivation 
of gonadotropic axis. Premature thelarche refers to the 
isolated development of breast tissue, without other pu-
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bertal signs, such as accelerated linear growth and ad-
vanced bone age, without impairment of adult height. 
It usually regresses over several months. In the largest 
cohort on outcome of girls with premature thelarche, 
13% of them developed progressive CPP (independent 
of the age of initial clinical presentation), which reinfor-
ce the need for long-term follow-up (25). Premature 
adrenarche is defined by the development of pubic or 
axillary hair growth due to increased concentrations of 
adrenal-derived androgens (mainly DHEA and DHEA 
sulfate). In this condition, adrenal disease (adrenal con-
genital hyperplasia, adrenocortical tumors) and other 
causes, such as contact with transdermal testosterone, 
topical corticosteroids cream, must be excluded. Ad-
vanced bone age might be present. Isolated prepubertal 
vaginal bleeding, with no other signs of puberty, are 
generally benign, acyclic and must be differentiated if 
it is dependent or not of hormonal action. Of note, 
prepubertal vaginal bleeding rarely represents the first 
manifestation of CPP. In addition, recurrent or conti-
nuous bleeding requires further investigation. Clinical 
indicators of pubertal progression should be carefully 
conducted in these patients with isolated forms. Labo-
ratory and imaging assessment of isolated variants of 
puberty can be limited to basal hormonal levels, bone 
age and pelvic ultrasound in girls (10,16,26).
Laboratory diagnosis
Hormonal assessment
Laboratory measurement of gonadotropins (mainly 
LH) at baseline and/or after stimulation with short-
-acting GnRH is recommended to document the ac-
tivation of the gonadal axis (10,15). The sensitivity of 
serum LH at baseline morning for diagnosis of CPP, 
mainly in girls, varies between 60 and 100%, depen-
ding on the cutoff value and laboratory methodology 
(16). Several laboratory methods with high sensitivity 
to measure gonadotropins levels are available, inclu-
ding immunofluorometric (IFMA), immunochemilu-
minescence (ICMA), and electrochemiluminescence 
(ECL). Of these, ICMA and ECL are the most com-
monly used. Basal LH values > 0.6 IU/L (IFMA) or 
> 0.3 IU/L (ICMA, ECL) in both genders are consi-
dered pubertal (16,27,28). Although a basal LH value 
in the prepubertal range does not exclude the diag-
nosis of CPP, GnRH stimulation test is not warran-
ted in most cases. Depending on clinical variables and 
their progression, a stimulation test with short-acting 
GnRH (intravenous gonadorelin, 100 µg) may be re-
commended. When short-acting GnRH is unavailab-
le (which is frequent in Brazil), LH measurement 30 
to 120 minutes after the first application of a monthly 
long-acting GnRH analog (GnRHa) may be an alter-
nativeto confirm the biochemical diagnosis of CPP in 
clinically suspected cases (29,30). The disadvantages 
of this strategy are the high cost, risk of local reaction 
and unavailability of GnRHa in some centers. For this 
reasons, the importance of basal LH in the diagnosis of 
CPP must be highlighted. A Canadian study demons-
trated the ability of basal LH, assessed by sensitive as-
say (ICMA), to predict clinical pubertal progression 
in 57 girls (31). Based on an algorithm, the authors 
found that a basal LH level ≥ 0.3 IU/L was indicative 
of pubertal progression while basal LH ≤ 0.2 IU/L in-
dicated no progression with 100% specifity and 90.5% 
sensitivity (31). The authors stated that basal LH levels 
in the diagnosis of CPP should be interpreted using 
local normative data and this approach may facilitate 
change in clinical practice avoiding the necessity of 
GnRH test, which is unfeasible in many centers, with 
cost savings (31). We demonstrated that basal LH > 
0.6 U/L, measured by IFMA, was able to diagnosis 
CPP in 62.7% of girls and 71.4% of boys (31). Using 
ICMA and ECLIA, we suggest consider the cutoff of 
basal LH of 0.3 U/L as indicative of CPP, avoiding the 
necessity of GnRH stimulation test. The distinct cutoff 
values of basal or GnRH-stimulated LH that indicate 
activation of the HPG axis are summarized in Table 2 
(27,28,30-38).
In girls, serum levels of E2 are not used to diagnose 
CPP, considering their low sensitivity and large over-
lap between normal prepubertal and pubertal children 
(26). In boys, serum total T is sensitive to diagnose 
precocious puberty but insufficient to determine the 
differential diagnosis between central and peripheral 
CPP, which is established from LH levels. Also in the 
male gender, measurement of β-hCG is always recom-
mended. Measurement of basal or GnRH-stimulated 
FSH is not useful in the diagnosis of CPP, but when the 
levels are low or suppressed, they strongly suggest the 
diagnosis of peripheral precocious puberty (10). Levels 
of gonadotropins and sex steroid hormones in children 
below the age of 2 years should be interpreted with 
caution since they are often increased at this age in as-
sociation with the physiological minipuberty.
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Imaging
Bone age (BA) is obtained with an X-ray of the nondo-
minant wrist and hand and estimated by different me-
thods, of which Greulich and Pyle’s is the most com-
monly used (39). In patients with precocious puberty, 
BA is often advanced, and when the advancement ex-
ceeds either one year or two standard deviations (SD), 
it is considered significant. BA is used to predict adult 
height by the Bayley-Pinneau method (40), although 
this method has low accuracy. Bayley-Pinneau tables for 
average BA should be preferred over those that use ac-
celerated BA, since the latter overestimate adult height 
(41,42). Pelvic ultrasonography is not used in the diag-
nosis of precocious puberty, but in girls, it helps deter-
mine the uterine and ovarian volume, and is a sensitive 
method to detect cysts and neoplastic lesions. An ova-
rian volume > 1.8 mL and uterine length > 3.4 cm in-
dicate hormonal stimulation and may be an additional 
laboratory parameter to evaluate girls with precocious 
puberty (16). Microcysts and ovarian follicles are nor-
mal findings in approximately 40% of prepubertal girls. 
Some studies have demonstrated that pelvic ultrasono-
graphy and uterine artery Doppler findings are useful 
to establish a differential diagnosis between isolated 
premature thelarche and progressive CPP. This asses-
sment is based on the pulsatility index (PI) of the ute-
rine artery (a difference between the peak systolic and 
end-diastolic flow divided by the flow velocity). Ho-
wever, this method requires an experienced examiner 
(43). After laboratory confirmation of CPP, anatomical 
assessment of the central nervous system (CNS) should 
be performed in all patients, preferably by magnetic 
resonance imaging (MRI) (10,44). Computed tomo-
graphy of the brain may identify CNS tumors, mainly 
calcified ones, but it has low sensitivity to detect small 
hamartomas. 
Molecular studies
In all cases of idiopathic CPP with or without familial 
history, molecular study of the makorin ring-finger 3 
(MKRN3) gene, recently implicated in the genetic etio-
logy of CPP, is indicated and may elucidate the genetic 
basis of the CPP, with no implication on diagnosis and 
therapeutic management (26). MKRN3 has a potential 
inhibitory effect on GnRH secretion and inactivating 
MKRN3 mutations have been identified in families from 
several geographical origins (12). In fact, MKRN3 repre-
sents the most common genetic cause of CPP (Table 1). 
In familial CPP, MKRN3 defects were found in about 
30% of families (45) while in patients with apparently spo-
radic CPP, MKRN3 defects were detected in about 8% of 
cases (12). In theses cases, genetic counseling should be 
considered in affected patients and their families.
Objectives and indications of pubertal arrest
The treatment of precocious puberty aims to interrupt 
the sexual maturation until the normal age for pubertal 
development is reached, revert or stabilize the sexual 
Table 2. Cutoff values of basal and GnRH-stimulated LH for diagnosis of central precocious puberty
Author Method Basal LH  (IU/L) GnRH LH peak after GnRH (IU/L)
Neely and cols., 1995 (32) ICMA 0.15 Gonadorelin 100 ug IV 5.0
Brito and cols., 1999 (27) IFMA 0.6 Gonadorelin 100 ug IV 6.9 (F)
9.6 (M)
Brito and cols., 2004 (30) IFMA 0.6 Leuprorelin acetate 3.75 mg 10.0
Houk and cols., 2009 (33) ICMA
IFMA
0.83
1.05
N/A N/A
Pasternak and cols., 2012 (34) ICMA 0.1 Gonadorelin 100 ug IV 4.9
Sathasivam and cols., 2010 (35) ICMA 0.3 Leuprorelin acetate 20 ug/kg SC 5.0
Resende and cols., 2007 (28) ICMA
IFMA
0.2
0.6
Gonadorelin 100 ug IV 4.1 (M); 3.3 (F)
3.3 (M); 4.2 (F)
Lee and cols., 2013 (36) ECLIA 0.1 Gonadorelin 100 ug IV 5.0 (F)
Freire and cols., 2013 (37) IFMA
ECLIA
N/A Triptorelin 
0.1 mg/m2, maximum of 0.1 mg SC
7.0 
8.0 
Bizarri and cols., 2014 (38) ICMA > 0.2 Gonadorelin 100 ug IV 5.0
ICMA: immunochemiluminescence; IFMA: immunofluorimetric; ECLIA: eletrochemiluminescence; SC: subcutaneous; IV: intravenous; F: female; M: male; N/A: not available.
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characteristics, delay the skeletal maturation, preserve 
the normal height potential (within the range of the 
target height), avoid body disproportions, and promo-
te the psychosocial adjustment of the patient and his or 
her family. It also helps to prevent pregnancy at an early 
age, and reduce the risk of sexual abuse, early initia-
tion of sexual activity, and estrogen-dependent cancer 
(mainly breast cancer) related to the occurrence of early 
menarche (10,44,46).
Pubertal arrest is indicated in patients with progres-
sive precocious puberty of any etiology, accelerated 
pubertal development (progression from one puber-
tal stage to another in a shorter period than normal), 
potential of abnormal final stature [prediction of final 
height below the 2.5th percentile; prediction of final 
height below the target height (± 8.5 cm); height SD 
for BA below -2; loss of height potential during fol-
low-up (44)]. Clinical and anthropometric data and 
BA advance are crucial for the decision to treat or not 
CPP. A period of 3-6 months follow-up can be useful 
to evaluate the “progressive” pattern of CPP. There is 
no consensus about the recommendation of pubertal 
arrest exclusively for psychosocial reasons (behavioral 
disorders, emotional immaturity, mental retardation, 
seizures) (44). In early and fast puberty, pubertal arrest 
may be beneficial (24,47).
Treatment of central precocious puberty
The treatment of choice for CPP is GnRHa (15,44), a 
synthetic decapeptide that binds to the GnRH receptor 
in the pituitary with more stability and duration, and 
is resistant to protease degradation, which prolongs its 
half-life. GnRHa acts on the anterior pituitary, com-
peting for GnRH receptor with endogenous GnRH, 
promoting endocytosis and reducing the amount of 
GnRH receptors (“down-regulation”) (46-48). Ini-
tially, GnRHa stimulates the synthesis and secretion of 
LH and FSH but when it is administered chronically, 
GnRHa suppresses the production of these hormones, 
which in turn suppress the production of sex steroid 
hormones by the gonads (28,48). Of the available 
GnRHa, leuprorelin acetate (LA) and triptorelin are the 
most commonly used, and their efficacy and safety on 
the treatment of CPP has been demonstrated by several 
studies. The dose of GnRHa used to treat CPP is 75-
100 µg/kg. In practice, this corresponds to a 3.75 mg 
administered intramuscularly or subcutaneously every 
28 days. Although some American groups recommend 
higher GnRHa doses (200-300 µg/kg), a monthly 7.5 mg 
dose has failed to show superior clinical results to ini-
tiate pubertal arrest (49). In recent years, more conve-
nient preparations with trimonthly dosing became avai-
lable, such as LA 11.25 mg, 22.5 mg, and 30 mg, with 
several studies demonstrating their efficacy and safety 
compared with those of monthly GnRHa. However, 
long-term follow-up results are still lacking (49-51). In 
Brazil, the recent approval of 3-month depot LA 11.25 
mg to treat CPP has improved dosing convenience and 
adherence, and brought satisfactory therapeutic results. 
Pubertal arrest may be initially obtained with 1-month 
depot (3.75 mg or 7.5 mg) or 3-month depot (11.25 
mg) dosages. A flowchart of CPP treatment is presen-
ted in Figure 2.
A subdermal implant of prolonged action that re-
leases therapeutic doses of GnRHa for 12 to 24 mon-
ths (histrelin 50 mg) has advantages and disadvantages 
over 1-month and 3-month depot GnRHa (52). The 
advantages include the abolishment of periodic subcu-
taneous or intramuscular administration, but the risk 
of reactions at the implant site, spontaneous extrusion, 
and local infection are the main undesirable side effects 
of this therapy. This treatment option is still unavailable 
in Brazil.
GnRHa are generally well tolerated, and their side 
effects are infrequent and include local allergic reac-
tions (5%-10% of the cases), headache, abdominal pain, 
vaginal bleeding after the first GnRHa dose, nausea, 
vasomotor symptoms due to hypoestrogenism and 
hyperprolactinemia, and rarely, anaphylaxis (10,44). 
These effects may be mild to severe in intensity. Atten-
tion should be given to local allergic reaction, charac-
terized by the development of a sterile abscess, which 
impairs the absorption of GnRHa that fails to suppress 
the hormonal secretion (53). In these cases, medro-
xyprogesterone acetate (MPA) or cyproterone acetate 
(CPA) represent therapeutic options. Both MPA and 
CPA are useful in blocking puberty progression, but 
have no beneficial impact on final height. MPA inhi-
bits central gonadotropin release by acting on hypo-
thalamic pulse generator, and it also directly inhibits 
gonadal steroidigenesis by inhibiting 3 betahydroxys-
teroid dehydrogenase 2 enzyme (16,19). In addition, 
MPA has a glucocorticoid mimetic action resulting in 
adrenocorticotrophic hormone (ACTH) suppression, 
hypertension, development of cushingoid habitus, and 
bone mineral loss. MPA dosage varies from 50 mg to 
150 mg per month (depot intramuscular injection) 
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Advantages of MPA include its low cost, easily admi-
nistration, and established efficacy in blocking puberty 
progression (16,19). CPA has antiandrogenic activity, 
competing with testosterone for its receptor in peri-
pheral tissues and an additional progestational action at 
the pituitary level, partially suppressing gonadotropin 
secretion. The usual CPA daily oral doses are 50 to 100 
mg/m2 (16). CPA side effects include gastrointestinal 
symptoms and gynecomastia in the male. Due to its 
ACTH and cortisol suppressing effect, laboratory hy-
poadrenalism can occur with CPA use, deserving special 
attention in stressful situation (16,19). Of note, these 
therapeutic options must be considered only when Gn-
RHa are not available or, as above-mentioned, in case 
of local reaction.
Surgical treatment of CNS lesions associated with 
CPP is indicated for both congenital and acquired mal-
formations (11,54). Other treatment modalities, such 
as chemotherapy or radiotherapy, are reserved for germ 
cell tumors. Treatment with surgery does not preclude 
clinical therapy with GnRHa (10,11,15,54). Surgical 
therapy for hypothalamic hamartomas is reserved for 
large lesions associated with epilepsy refractory to cli-
nical treatment, signs of intracranial hypertension, or 
rare cases of tumor growth, when a differential diag-
nosis must be established with other lesions, such as 
astrocytoma and glioma (55).
Treatment monitoring in central precocious puberty
The treatment of CPP with GnRHa is monitored by cli-
nical and laboratory evaluations (10,15). Parameters of 
good clinical control include stabilization or regression 
of secondary sexual characteristics, decrease in height 
velocity, and improvement in final height prediction. 
BA must be monitored annually in cases with adequa-
te clinical and hormonal control, or semiannually in 
cases suggesting inadequate control. The laboratory 
parameter of choice is the measurement of LH values 
after monthly or trimonthly GnRHa, aiming at levels 
below 4 IU/L (determined by IFMA, ICMA, or ECL) 
(10,16,28,29,50). Levels of E2 or T should be suppres-
sed before GnRHa administration (16,26,50). Patients 
with inadequate clinical and laboratory control that 
persists after an increase in GnRHa dose must have the 
etiological diagnosis of the precocious puberty carefully 
reevaluated (10). When the height velocity reduces mar-
kedly (below 4 cm/year), recombinant human growth 
1-month depot GnRHa 3.75 mg  28/28 days 
3-month depot GnRHa 11.25 mg  12/12 weeks (84 days)
Trimonthly clinical and laboratorial monitoring
Adequate control Inadequate control
1-month depot GnRHa 3.75 mg
Inadequate control
1-month depot GnRHa 7.5 mg
Clinical and laboratorial diagnosis of progressive CPP
3 – 6 months
Figure 2. Treatment flowchart of progressive central precocious puberty (CPP) with a long-acting GnRH analog (GnRHa).
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hormone (rGH) may be added to the treatment (56). 
This measure aims at increasing the height velocity and 
promoting height gain. The recommended rGH dose 
in this circumstance is 0.15 IU/kg/day administered 
subcutaneously. Few studies have assessed the impact 
of rGH administration on final height in patients with 
CPP (56-58). Two studies showed a benefit effect from 
adding rGH to GnRHa therapy in children with de-
creased growth during GnRHa therapy. In these non-
randomized studies, the mean final height was around 
7.5 cm greater than the pretreatment predicted height 
(56,57). In addition, 46 girls with early or precocious 
puberty adopted from developing countries were ran-
domized for treatment for 2-4 y with GnRHa, or with 
a combination of rGH and GnRHa. During treatment, 
the mean growth velocity in the rGH/GnRHa group 
was significantly higher and resulted in a higher final 
height (58). All in all, based on available literature, the 
association of rGH to GnRH cannot sistematically be 
recommended and the subset of CPP patients whose 
take some advantage with rGH addition was not de-
termined so far (44,58). Treatment withdrawal should 
take into account the chronological age of the patient 
and his or her psychosocial adequacy and desire. A BA 
around 12.5 years in girls and 13.5 years in boys indi-
cate the best moment to withdraw the therapy aiming 
at reaching a normal final height within the genetic po-
tential (10,15,44,46).
Long-term follow-up
Final height, body composition, bone mineral density, 
reproductive function, and psychological characteristics 
are parameters of interest in the long-term follow-up 
of patients treated with GnRHa. Evidence shows that 
the GnRHa treatment is beneficial in preserving the po-
tential genetic height, mainly in those girls who started 
treatement before 6 years of age (42,44,46,47). Con-
versely, CPP diagnosed after the age of 6 yr had redu-
ced post treatment height gain and compromised final 
height, probably due to pre treatment intrinsic changes 
in the growth plate according Lazar and cols. (24,47). 
In a Brazilian study involving 45 girls, we found no sig-
nificant association between chronological age at the 
start of therapy and posttreatment linear growth (42). 
Although cronological age at the onset of therapy was 
significantly and negatively associated with final height, 
most of the girls who achieved normal adult height 
started GnRHa therapy after the age of 6 yr, indicating 
that GnRHa therapy is effective in preserving the po-
tential genetic height in girls older than 6 yr (42). In 
fact, the main factors determining normal final height 
in girls with CPP treated with depot GnRHa were shor-
ter interval between the onset of puberty and onset of 
therapy, higher height SDS at the onset and end of the-
rapy, and target height (42). Finally, no benefits on final 
height was demonstrated in those girls with early or fast 
puberty, although benefits on psychosocial profile and 
in delay menarche should be considered (24,44,47).
Transitional changes in body composition and bone 
mass may occur without consequences in adulthood 
(44,47,59). With regard to reproductive function, stu-
dies indicate that menstruation occurs on average 16 
months after the treatment of CPP is withdrawn (with 
a variation of 2 to 61 months). Regular ovarian cycles 
occur in 60% to 96% of the patients, and infertility has 
not been reported (44,59). In females, an increased pre-
valence of polycystic ovary syndrome has been reported, 
although the findings are controversial (44,60). In ma-
les, a few studies that have been carried out have shown 
normal gonadal function (43). The few studies that have 
evaluated the psychosocial impact of CPP suggest that 
antisocial behavior is limited to adolescence and that 
there are no differences in psychosocial adjustment (44). 
However, there are no controlled studies evaluating the 
short- and long-term effects of the therapeutic interven-
tion with GnRHa on psychosocial characteristics.
CONCLUSIONS
Puberty is a multifactorial process. The clinical diagnosis 
of precocious puberty is not always easy, particularly in 
females and among variants of normal development (pre-
mature thelarche and constitutional growth and puberty 
acceleration) with progressive and nonprogressive pa-
thological conditions. The decision to treat CPP, mainly 
in girls, is based on clinical and anthropometric data, 
and bone age advance. Sometimes these data obtained 
at short-term follow-up do not recommend CPP treat-
ment. Although the biochemical diagnosis has shown 
significant improvement with more sensitive and specific 
immunoassays, standardization is still required due to the 
availability of several methods and protocols to measure 
basal and GnRH-stimulated LH. This fact results in dif-
ferent cutoff values to confirm the activation of the go-
nadal axis. Treatment with GnRHa has shown significant 
advances in recent years, with more convenient, effective, 
and safe dosages in the short- and long-term.
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Where you read: Should read:
INTRODUCTION
P uberty is a period of physical, hormonal, and psychological transition from childhood to 
adulthood, with accelerated linear growth and 
achievement of reproductive function. It is a complex 
and multifactorial process that includes genetic, 
metabolic, environmental, ethnic, geographic, and 
economic factors and results in reactivation of the 
hypothalamic-pituitary-gonadal (HPG) axis. An 
effective pubertal onset requires pulsatile hypothalamic 
secretion of GnRH stimulating the secretion of 
gonadotropins by the anterior pituitary gland (LH = 
luteinizing hormone and FSH = follicle-stimulating 
hormone). Gonadotropins stimulate the gonads and 
exert a negative feedback effect on the hypothalamus, 
whereas gonadal steroids (T = testosterone, produced by 
the testis, and E2 = estradiol, produced by the ovaries) 
inhibit both hypothalamus and anterior pituitary gland. 
This process is named gonadarche (1-3).
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